The Effect of Flaxseed Enriched Yogurt on the Glycemic Status and Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus: Randomized, Open-labeled, Controlled Study
- Author:
Nazila HASANIANI
1
;
Mehran RAHIMLOU
;
Amirhossein RAMEZANI AHMADI
;
Alireza MEHDIZADEH KHALIFANI
;
Mohammad ALIZADEH
Author Information
- Publication Type:Controlled Clinical Trial
- Keywords: Type 2 diabetes; Flaxseed; Yogurt; Blood pressure
- MeSH: Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Flax; Humans; Hypoglycemic Agents; Lipoproteins; Risk Factors; Triglycerides; Waist Circumference; Yogurt
- From:Clinical Nutrition Research 2019;8(4):284-295
- CountryRepublic of Korea
- Language:English
- Abstract: Flaxseed is one of the rich sources of α-linolenic acid and lignan. Flaxseed and its components have antioxidant, hypolipidemic and hypoglycemic effects. The study aimed to investigate the effect of flaxseed enriched yogurt on glycemic control, lipid profiles and blood pressure in patients with type 2 diabetes. A randomized, open-labeled, controlled clinical trial was conducted on 57 patients with type 2 diabetes. Participants were assigned to receive 200 g 2.5% fat yogurt containing 30-g flaxseed or plain yogurt daily for 8 weeks. Anthropometrics and biochemical parameters were evaluated at the beginning and end of the study. After 8 weeks of supplementation, Hemoglobin A1c was significantly decreased in the intervention group compared to control (p = 0.007). Also, at the end of the study, significant differences were seen between the flaxseed enriched yogurt and control groups in triglycerides and total cholesterol concentrations (p = 0.04 and p = 0.01), systolic blood pressure and diastolic blood pressure (p = 0.02 and p = 0.002, respectively). However, we did not find any difference between 2 groups in low-density lipoprotein, high-density lipoprotein, body weight and waist circumference (p > 0.05). Our results showed that the addition of flaxseed to yogurt can be effective in the management of type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02436369
